中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2014年
14期
1-2,3
,共3页
王英%罗浩虹%高洪泉%缪智辉%赵亚清
王英%囉浩虹%高洪泉%繆智輝%趙亞清
왕영%라호홍%고홍천%무지휘%조아청
人脐带血%间充质干细胞%定向诱导%糖尿病
人臍帶血%間充質榦細胞%定嚮誘導%糖尿病
인제대혈%간충질간세포%정향유도%당뇨병
Human umbilical cord blood%Mesenchymal stem cells%Induction%Diabetes rats
目的:研究人脐带血间充质干细胞向胰岛素分泌细胞分化的潜能及其移植后对糖尿病大鼠的治疗效果。方法体外分离培养HUCB-MSCs,在胰岛细胞培养条件下经药物定向诱导其分化;免疫组化对诱导细胞进行胰岛β细胞标记鉴定;双硫腙染色鉴定锌离子表达及检测胰岛样细胞的移植效果。结果 HUCB-MSCs经诱导后,免疫细胞化学染色显示表达人胰岛素;双硫腙染色呈棕红色;移植后2周,胰岛样细胞组血糖浓度明显降低。结论 HUCB-MSCs在体外诱导培养条件下,具有向胰岛素分泌细胞分化的潜能,这种细胞可能为Ⅰ型糖尿病提供一条新的治疗途径。
目的:研究人臍帶血間充質榦細胞嚮胰島素分泌細胞分化的潛能及其移植後對糖尿病大鼠的治療效果。方法體外分離培養HUCB-MSCs,在胰島細胞培養條件下經藥物定嚮誘導其分化;免疫組化對誘導細胞進行胰島β細胞標記鑒定;雙硫腙染色鑒定鋅離子錶達及檢測胰島樣細胞的移植效果。結果 HUCB-MSCs經誘導後,免疫細胞化學染色顯示錶達人胰島素;雙硫腙染色呈棕紅色;移植後2週,胰島樣細胞組血糖濃度明顯降低。結論 HUCB-MSCs在體外誘導培養條件下,具有嚮胰島素分泌細胞分化的潛能,這種細胞可能為Ⅰ型糖尿病提供一條新的治療途徑。
목적:연구인제대혈간충질간세포향이도소분비세포분화적잠능급기이식후대당뇨병대서적치료효과。방법체외분리배양HUCB-MSCs,재이도세포배양조건하경약물정향유도기분화;면역조화대유도세포진행이도β세포표기감정;쌍류종염색감정자리자표체급검측이도양세포적이식효과。결과 HUCB-MSCs경유도후,면역세포화학염색현시표체인이도소;쌍류종염색정종홍색;이식후2주,이도양세포조혈당농도명현강저。결론 HUCB-MSCs재체외유도배양조건하,구유향이도소분비세포분화적잠능,저충세포가능위Ⅰ형당뇨병제공일조신적치료도경。
Objective To explore the possibility of inducing the differentiation of human umbilical cord blood mesenchymal stem cells(HUCB-MSCs) into insulin secreting cells in vitro and the therapeutic efficacy on diabetic rats following transplantation.Methods We isolated and cultured HUCB-MSCs, and induced HUCB-MSCs to differentiate into insulin secreting cells in the islet cell culture condition. HUCB-MSCs of induction were detected by immunocytochemical Methods. Zinchydronium was detected by Dithizon staining. Transplantation efficiency of islet-like cells was detected.Results Under induction, immunocytochemical examination showed that the expression of human insulin was positive. Dithizon stain showed that the cytoplasm of HUCB-MSCs was stained in brownish red color after induction. At 2 weeks following transplantation, blood glucose concentration in the islet-like cell group significantly reduced.Conclusion HUCB-MSCs can be differentiated into insulin secreting cells in vitro. HUCB-MSCs have the potential to become an excellent candidate in β cell replacement therapy of typeⅠdiabetes.